Brokerages Set BioNTech SE (NASDAQ:BNTX) Price Target at $131.92

Shares of BioNTech SE (NASDAQ:BNTX) have been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $131.92.

A number of equities analysts have commented on BNTX shares. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. HSBC boosted their price objective on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Bank of America lifted their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and increased their price target for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. Finally, TD Cowen dropped their price objective on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its stake in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares in the last quarter. Covestor Ltd boosted its stake in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the period. EverSource Wealth Advisors LLC boosted its position in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. Crewe Advisors LLC purchased a new stake in BioNTech during the 1st quarter worth about $75,000. Finally, American National Bank acquired a new stake in BioNTech in the first quarter valued at approximately $81,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Performance

Shares of NASDAQ BNTX opened at $120.14 on Tuesday. The stock has a market cap of $28.56 billion, a PE ratio of 240.28 and a beta of 0.24. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a fifty day moving average price of $101.74 and a 200-day moving average price of $93.56. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The business had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s revenue for the quarter was down 23.3% compared to the same quarter last year. During the same period last year, the business posted ($0.86) EPS. Equities analysts anticipate that BioNTech will post -3.04 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.